Evaluation value of combined detection of serum CYFRA21-1,CAR and IL-6 in the efficacy of concurrent chemoradiotherapy in esophageal cancer
Objective To evaluate the efficacy of simultaneous chemoradiotherapy in esophageal carcinoma(EC)with serum cytokeratin 19 fragment antigen 21-1(CYFRA21-1),C-reactive protein to albumin ratio(CAR)and interleukin-6(IL-6).Methods A total of 93 patients diagnosed with esophageal cancer by pa-thology were selected as the study subjects from January 7,2020 to July 20,2023 in the Radiotherapy depart-ment at Fuyang Cancer Hospital,Anhui Province.Based on the pathological changes of tumor tissues after treat-ment,they were divided into an effective group(n=62)and an ineffective group(n=31).The clinical data and laboratory indicators of the two groups were compared,and the correlation between serum CYFRA21-1,CAR and IL-6 and the efficacy of concurrent chemoradiotherapy for esophageal cancer was analyzed using multivari-ate logistic analysis.A receiver operating characteristic curve(ROC)was drawn to evaluate the diagnostic value of the combined detection of serum CYFRA21-1,CAR and IL-6 on the efficacy of concurrent chemoradio-therapy for esophageal cancer.Results Two groups of patients were compared based on age,lymph node me-tastasis,clinical stage,and serum levels of CYFRA21-1,CAR,and IL-6.The differences were statistically sig-nificant(P<0.05).Multivariate logistic regression analysis showed that increasing age,lymph node metastasis,clinical stage Ⅲ,and higher serum levels of CYFRA21-1,CAR,and IL-6 were all independent risk factors af-fecting the efficacy of concurrent chemoradiotherapy for EC(P<0.05).The ROC curve showed that the area un-der the curve for serum CYFRA21-1,CAR,IL-6,and the combined detection of the three were 0.989,0.726,0.727 and 0.995,respectively.Conclusion Serum CYFRA21-1,CAR,and IL-6 can effectively predict the ef-ficacy of concurrent chemoradiotherapy for esophageal cancer.The combined use of the three markers has a higher predictive value.
NETL
NSTL
万方数据
